N-6 substituted adenosine derivatives as cardiac vasodilators
US5043325A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 13, 1986 |
| Grant date | Aug 27, 1991 |
| Priority date | — |
| Expiry date | Feb 13, 2006 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
New, N-6 monosubstituted adenosine derivatives are disclosed which have significant cardiac vasodilatory effect. The compounds of the invention include 6-(cyclo-butyl amino)-9-(.beta.-D-ribofuranosyl)-9H-purine, 6-(2-methyl-2-phenyl hydrazino)-9-(.beta.-D-ribofuranosyl)-9H-purine, and compounds of the general formula: ##STR1## wherein R.sub.1 is H, lower alkyl, lower alkoxy, alkylamino, or arylamino, R.sub.2 is H, lower alkyl, hydroxymethyl, phenyl or substituted phenyl, R.sub.3 is H, lower alkyl, phenyl, substituted phenyl, R.sub.3 is H, lower alkyl, phenyl, substituted phenyl, 2 or 3-thienyl, or 2 or 3-pyridyl, R.sub.4 is H or lower alkyl, and R.sub.5 is H or lower acyl. Particularly active as a cardiac vasodilator is the compound (-)-6-(R-1-phenyl-2-butyl amino)-9-(.beta.-D-ribofuranosyl)-9H-purine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.